NSAIDs damage the gut through two separate mechanisms: prostaglandin-mediated loss of mucosal defences (acid-driven, addressed by PPIs) and direct cytotoxic injury to the small intestine (acid-independent, which PPIs do not reach and may worsen via microbiome disruption). REZCUE is positioned to close that gap.
It combines pharmaceutical-strength zinc L-carnosine (polaprezinc), which adheres directly to damaged mucosa and delivers zinc locally, with L-glutamine, which fuels enterocyte repair and restocks glutathione from within. The two act through distinct, complementary routes rather than duplicating each other's mechanism.
The paper reviews the evidence for each ingredient individually in NSAID-specific injury — including a human capsule-endoscopy trial for zinc L-carnosine and a permeability study for glutamine — and sets out dosing (4 scoops/day, taken alongside the NSAID for its full duration, not before or after) along with safety considerations: copper depletion on long-term use, levothyroxine interaction, and contraindications in pregnancy, GI/liver cancer, and severe organ disease.
